Real-World Use of Palbociclib Monotherapy in Retroperitoneal Liposarcomas at a Large Volume Sarcoma Center

Authors

Elise F Nassif
Brandon Cope
Raymond Traweek
Russell G Witt
Derek J Erstad
Christopher P Scally
Prapassorn Thirasastr
Maria Alejandra Zarzour
Joseph Ludwig
Robert Benjamin
Andrew J Bishop
B Ashleigh Guadagnolo
Davis Ingram
Khalida Wani
Wei-Lien Wang
Alexander J Lazar
Keila E Torres
Kelly K Hunt
Barry W Feig
Christina L Roland
Neeta Somaiah
Emily Z Keung

Publication Date

6-15-2022

Journal

International Journal of Cancer

Abstract

Palbociclib has been evaluated in early phase trials for well-differentiated liposarcoma (WDLPS) and dedifferentiated liposarcoma (DDLPS) patients, with reported median progression-free survival (PFS) of 18 weeks. Here, we report on real-world use and surgical outcomes associated with palbociclib treatment. We retrospectively reviewed 61 consecutive patients with retroperitoneal WDLPS (n = 14) or DDLPS (n = 47) treated with palbociclib monotherapy between 1 March 2016 and 28 February 2021 at The University of Texas MD Anderson Cancer Center. At palbociclib initiation, median age was 64 (interquartile range [IQR] 56-72). In WDLPS and DDLPS cohorts, the median number of prior systemic treatments was 0 (IQR 0-0) and 2 (IQR 0-4), respectively. Median number of prior surgeries was 2 (WDLPS IQR 1-2.75) and 2 (DDLPS IQR 1-3). Median PFS was 9.2 (WDLPS IQR 3.9-21.9) and 2.6 months (DDLPS IQR 2.0-6.1), with median time on treatment of 7.4 months (WDLPS IQR 3.5-14.2) and 2.7 months (DDLPS IQR 2.0-5.7). Twelve patients ultimately underwent surgical resection. Resections were macroscopically complete (R0/R1) in half (n = 6/12), among whom only one patient experienced relapse after resection (median follow-up 7.5 months). All patients who underwent macroscopically incomplete resections progressed after surgery with median time to progression of 3.3 months (IQR 2.3-4.4). Surgery after palbociclib treatment was not associated with improved overall survival. Efficacy of palbociclib monotherapy for patients with advanced WDLPS and DDLPS is disappointing. While palbociclib may have been used to delay surgery, there was no clear benefit from treatment and few patients achieved prolonged tumor control.

Keywords

Humans, Liposarcoma, Middle Aged, Neoplasm Recurrence, Local, Piperazines, Pyridines, Retroperitoneal Neoplasms, Retrospective Studies, Soft Tissue Neoplasms, PD-L1, liposarcoma, palbociclib, retroperitoneal, surgery

DOI

10.1002/ijc.33956

PMID

35128664

PMCID

PMC12085978

PubMedCentral® Posted Date

5-18-2025

PubMedCentral® Full Text Version

Author MSS

Published Open-Access

yes